局限性前列腺癌立体定向体部放疗:逾6000例前瞻性研究的系统综述与荟萃分析
该系统综述与荟萃分析纳入38项前瞻性研究、共6116例接受治愈性SBRT的局限性前列腺癌患者,中位随访39个月。5年和7年生化无复发生存率分别为95.3%和93.7%,晚期≥3级泌尿和胃肠毒性分别为2.0%和1.1%,患者报告生活质量在2年内回归基线。SBRT剂量增加与生化控制改善相关,但也与晚期≥3级泌尿毒性增加相关。
要点
- 5年和7年生化无复发生存率分别为95.3%和93.7%。
- 晚期≥3级泌尿毒性和胃肠毒性分别为2.0%和1.1%。
- SBRT后2年泌尿与肠道域评分回归基线。
核心结论
- 前列腺SBRT具有充分的前瞻性证据支持,肿瘤控制、患者报告生活质量和毒性水平均良好。
- SBRT证据足以支持其作为局限性前列腺癌的标准治疗选择,同时正在进行的试验评估其潜在优越性。
研究设计与样本
- 系统检索PubMed/Medline和EMBASE中1990年1月至2018年1月发表的原创文章,并补充2013年1月至2018年3月可提取足够数据的摘要。
- 纳入所有评估治愈性前列腺SBRT治疗局限性前列腺癌、报告bRFS、医生报告毒性和患者报告生活质量且随访至少1年的前瞻性系列。
- 共识别38项独特前瞻性系列,合计6116例患者;采用随机效应模型进行荟萃分析,用I2和Cochran Q检验评估异质性,用Hartung-Knapp法进行荟萃回归。
主要发现
- 所有患者中位随访39个月(范围12-115个月)。
- 5年和7年bRFS分别为95.3%(95%CI 91.3%-97.5%)和93.7%(95%CI 91.4%-95.5%)。
- 估计晚期≥3级泌尿毒性和胃肠毒性分别为2.0%(95%CI 1.4%-2.8%)和1.1%(95%CI 0.6%-2.0%)。
- SBRT后2年,EPIC泌尿域和肠道域评分回归基线;SBRT剂量增加与生化控制改善相关(P=.018),但与晚期≥3级泌尿毒性增加相关(P=.014)。
关键数值与推荐
- 5年bRFS为95.3%(95%CI 91.3%-97.5%),7年bRFS为93.7%(95%CI 91.4%-95.5%)。
- 晚期≥3级泌尿毒性为2.0%(95%CI 1.4%-2.8%),晚期≥3级胃肠毒性为1.1%(95%CI 0.6%-2.0%)。
- SBRT剂量增加与生化控制改善相关(P=.018),与晚期≥3级泌尿毒性增加相关(P=.014)。
临床怎么用
- 前列腺SBRT可作为局限性前列腺癌的标准治疗选择之一。
- 采用SBRT时应权衡剂量增加带来的生化控制改善与晚期≥3级泌尿毒性增加风险。
- 应向患者说明SBRT后泌尿和肠道生活质量多在2年内回归基线。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Utilization of stereotactic body radiation therapy (SBRT) for treatment of localized prostate cancer is increasing. Guidelines and payers variably support the use of prostate SBRT. We therefore sought to systematically analyze biochemical recurrence-free survival (bRFS), physician-reported toxicity, and patient-reported outcomes after prostate SBRT. METHODS AND MATERIALS: A systematic search leveraging Medline via PubMed and EMBASE for original articles published between January 1990 and January 2018 was performed. This was supplemented by abstracts with sufficient extractable data from January 2013 to March 2018. All prospective series assessing curative-intent prostate SBRT for localized prostate cancer reporting bRFS, physician-reported toxicity, and patient-reported quality of life with a minimum of 1-year follow-up were included. The study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Meta-analyses were performed with random-effect modeling. Extent of heterogeneity between studies was determined by the I2 and Cochran's Q tests. Meta-regression was performed using Hartung-Knapp methods. RESULTS: Thirty-eight unique prospective series were identified comprising 6116 patients. Median follow-up was 39 months across all patients (range, 12-115 months). Ninety-two percent, 78%, and 38% of studies included low, intermediate, and high-risk patients. Overall, 5- and 7-year bRFS rates were 95.3% (95% confidence interval [CI], 91.3%-97.5%) and 93.7% (95% CI, 91.4%-95.5%), respectively. Estimated late grade ≥3 genitourinary and gastrointestinal toxicity rates were 2.0% (95% CI, 1.4%-2.8%) and 1.1% (95% CI, 0.6%-2.0%), respectively. By 2 years post-SBRT, Expanded Prostate Cancer Index Composite urinary and bowel domain scores returned to baseline. Increasing dose of SBRT was associated with improved biochemical control (P = .018) but worse late grade ≥3 GU toxicity (P = .014). CONCLUSIONS: Prostate SBRT has substantial prospective evidence supporting its use, with favorable tumor control, patient-reported quality of life, and levels of toxicity demonstrated. SBRT has sufficient evidence to be supported as a standard treatment option for localized prostate cancer while ongoing trials assess its potential superiority.
引用
- Jackson WC, Silva J, Hartman HE, et al. Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. Int J Radiat Oncol Biol Phys. 2019. PMID: 30959121. doi:10.1016/j.ijrobp.2019.03.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。